TY - JOUR
T1 - Why haven't we solved the addiction crisis?
AU - Blum, Kenneth
AU - Bowirrat, Abdalla
AU - Gomez, Luis Llanos
AU - Downs, B. William
AU - Bagchi, Debasis
AU - Barh, Debmalya
AU - Modestino, Edward J.
AU - Baron, David
AU - McLaughlin, Thomas
AU - Thanos, Panayotis
AU - Ceccanti, Mauro
AU - Elman, Igor
AU - Badgaiyan, Rajendra D.
AU - Dennen, Catherine
AU - Gupta, Ashim
AU - Braverman, Eric R.
AU - Gold, Mark S.
N1 - Publisher Copyright: © 2022
PY - 2022/11/15
Y1 - 2022/11/15
N2 - The current addiction crisis has destroyed a multitude of lives, leaving millions of fatalities worldwide in its wake. At the same time, various governmental agencies dedicated to solving this seemingly never-ending dilemma have not yet succeeded or delivered on their promises. We understand that addictive behavioral seeking is a multi-faceted neurobiological and spiritually complicated phenomenon. However, although the substitution replacement approach, especially to treat Opioid Use Disorder (OUD), has importance for harm reduction in the short term, it does not bring about a harm-free recovery or prevention. Instead, we propose a promising novel approach that uses genetic risk testing with induction of dopamine homeostasis and an objective Brain Health Check during youth. Our model involves a six-hit approach known as the “Reward Dysregulation Syndrome Solution System,” which can identify addiction risk and target the root cause of addiction, dopamine dysregulation. While we applaud all past sophisticated neurogenetic and neuropharmacological research, our opinion is that in the long term, addiction scientists and clinicians might characterize preaddiction using tests; for example, administering the validated RDSQuestionarre29, genetic risk assessment, a modified brain health check, or diagnostic framing of mild to moderate Substance Use Disorder (SUD). The preaddiction concept could incentivize the development of interventions to prevent addiction from developing in the first place and target and treat neurotransmitter imbalances and other early indications of addiction. WC 222.
AB - The current addiction crisis has destroyed a multitude of lives, leaving millions of fatalities worldwide in its wake. At the same time, various governmental agencies dedicated to solving this seemingly never-ending dilemma have not yet succeeded or delivered on their promises. We understand that addictive behavioral seeking is a multi-faceted neurobiological and spiritually complicated phenomenon. However, although the substitution replacement approach, especially to treat Opioid Use Disorder (OUD), has importance for harm reduction in the short term, it does not bring about a harm-free recovery or prevention. Instead, we propose a promising novel approach that uses genetic risk testing with induction of dopamine homeostasis and an objective Brain Health Check during youth. Our model involves a six-hit approach known as the “Reward Dysregulation Syndrome Solution System,” which can identify addiction risk and target the root cause of addiction, dopamine dysregulation. While we applaud all past sophisticated neurogenetic and neuropharmacological research, our opinion is that in the long term, addiction scientists and clinicians might characterize preaddiction using tests; for example, administering the validated RDSQuestionarre29, genetic risk assessment, a modified brain health check, or diagnostic framing of mild to moderate Substance Use Disorder (SUD). The preaddiction concept could incentivize the development of interventions to prevent addiction from developing in the first place and target and treat neurotransmitter imbalances and other early indications of addiction. WC 222.
KW - Addiction
KW - Dopamine homeostasis
KW - Dopamine regulation
KW - Genetic testing
KW - Neuroimaging
UR - http://www.scopus.com/inward/record.url?scp=85137288687&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jns.2022.120404
DO - https://doi.org/10.1016/j.jns.2022.120404
M3 - مقالة مرجعية
SN - 0022-510X
VL - 442
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
M1 - 120404
ER -